MDPHP is assumed to act mainly to be a strong norepinephrine-dopamine reuptake inhibitor (NDRI). Lessened re-uptake of norepinephrine and dopamine brings about bigger concentrations of The 2 catecholamine neurotransmitters within the synaptic cleft, or gap involving neurons. The result of this inhibition is an enhanced and extended concentration an